ZE77-0273 / Eilean Therapeutics - LARVOL DELTA

A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC (AACR-NCI-EORTC 2025) - "Conclusions ZE77-0273 is a promising, AI-designed, reversible pan-EGFR inhibitor with broad activity across classical, atypical, and resistance EGFR mutations. Its favorable PK profile, preclinical efficacy, and broad mutational coverage support its advancement toward clinical development in EGFR-mutant NSCLC."

Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PRNewswire)

Preclinical • Non Small Cell Lung Cancer